Table 8

Application of IHC in primary diagnosis in confirmed cases (some patterns, partially overlapping cases)

Year

Confirmed cases

IHC/markers in primary diagnostics


1980-2002

49 (100%)

19 (39%)

No IHC performed

4 (8%)

No information available about eventual IHC use

26 (53%)

IHC, 1 till 18 markers

No specific positive MM markers

1988-1999

7 (14%)

CEA, Vimentin and Pan-Cytokeratin

Broad spectrum of non-specific markers

1996, 1997

2 (4%)

15/18 markers, 1st one incl. positive marker HBME-1, otherwise no specific positive MM markers

Positive MM markers

1998-2002

8 (16%)

Calretinin, in all but one (1998) of cases combined with other markers, two cases with another positive marker - Thrombomodulin and HBME-1, respectively (n = 1-7)

Negative MM markers

1988-2002

17 (35%)

CEA, in all but one (1990) of cases combined with other markers (n = 1-18)

1996, 2002

2 (4%)

CD15, combined with, amongst other markers, CEA and Ber-Ep4 (n = 15, 7)

1996-2002

10 (20%)

Ber-Ep4, combined with other markers (n = 4-15)


Sandeck et al. Diagnostic Pathology 2010 5:47   doi:10.1186/1746-1596-5-47

Open Data